Letrozole (1mg/capsule), 60 Capsules
$77.95
Letrozole is a third-generation non-steroidal aromatase inhibitor that selectively targets CYP19A1 (aromatase), a cytochrome P450 enzyme responsible for catalyzing key steps in estrogen biosynthesis pathways. By inhibiting aromatase activity, letrozole serves as a valuable research tool for investigating enzyme… CAS: 112809-51-5 | Formula: C17H11N5 | Content: 60 mg (1 mg per capsule) | Research use only | Third-party lab tested.
Buy Letrozole (1mg/capsule), 60 Capsules – Swiss Chems USA
Letrozole (1mg/capsule), 60 Capsules — Research Overview
Letrozole is a third-generation non-steroidal aromatase inhibitor that selectively targets CYP19A1 (aromatase), a cytochrome P450 enzyme responsible for catalyzing key steps in estrogen biosynthesis pathways. By inhibiting aromatase activity, letrozole serves as a valuable research tool for investigating enzyme kinetics, substrate-enzyme interactions, steroidogenic pathway regulation, and feedback mechanisms associated with hormone biosynthesis networks. Experimental studies have examined its effects on CYP19A1-mediated catalytic processes, transcriptional regulation of steroidogenic pathways, and interactions within endocrine signaling systems. Research applications include aromatase enzyme pharmacology, estrogen biosynthesis pathway investigation, steroidogenic enzyme research, and comparative studies of aromatase inhibitor pharmacology.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
Intended use: This material is supplied for laboratory and in-vitro research only. It is not a drug, food, or cosmetic and is not intended for human or animal consumption.
Letrozole (1mg/capsule), 60 Capsules Chemical Properties
| Property | Specification |
|---|---|
| Chemical Formula | C17H11N5 |
| Synonyms | Femara (trade name), CGS 20267, 4,4′-[(1H-1,2,4-triazol-1-yl)methylene]dibenzonitrile |
| Molar Mass | 285.31 g/mol |
| CAS Number | 112809-51-5 |
| PubChem CID | 3902 |
| Total Compound Content | 60 mg (1 mg per capsule) |
| Shelf Life | 36 months |
Letrozole (1mg/capsule), 60 Capsules Research Applications
Letrozole is a triazole-class, third-generation non-steroidal aromatase inhibitor that selectively targets CYP19A1 (aromatase) through coordination of its triazole nitrogen with the enzyme’s haem iron center. This interaction inhibits the catalytic activity of aromatase, making letrozole a valuable research tool for investigating enzyme kinetics, substrate-enzyme interactions, steroidogenic pathway regulation, and cytochrome P450-mediated catalytic mechanisms. Experimental studies have examined its effects on aromatase-associated signaling pathways, transcriptional regulation of steroidogenic enzymes, and molecular processes governing hormone biosynthesis networks. Research applications include aromatase enzyme pharmacology, CYP19A1 inhibition studies, steroidogenic pathway investigation, enzyme-selectivity research, and comparative analysis of aromatase inhibitor pharmacology. Supplied in 1 mg capsules. Independently third-party HPLC-tested; COA available per batch.
Letrozole (1mg/capsule), 60 Capsules Lab Results & Certificates of Analysis
Third-party analytical reports associated with this research compound:
Letrozole (1mg/capsule), 60 Capsules Frequently Asked Questions
How does letrozole’s mechanism of aromatase inhibition differ from steroidal aromatase inhibitors?
Letrozole is a non-steroidal aromatase inhibitor that interacts reversibly with CYP19A1 through coordination of its triazole nitrogen with the enzyme’s haem iron center. Steroidal aromatase inhibitors utilize a different structural framework and interact with the enzyme through distinct molecular mechanisms. These differences make letrozole a valuable research tool for comparative investigations of aromatase inhibition, enzyme-ligand interactions, active-site binding characteristics, and CYP19A1 pharmacology.
What makes letrozole useful for aromatase pathway research?
Letrozole is a highly selective CYP19A1 inhibitor widely used to investigate aromatase-mediated catalytic processes, steroidogenic pathway regulation, enzyme kinetics, and substrate-enzyme interactions. Experimental studies employ letrozole to examine the role of aromatase within hormone biosynthesis networks, transcriptional regulation of steroidogenic pathways, and the molecular consequences of selective CYP19A1 inhibition.
What is the potency of letrozole in aromatase enzyme studies?
Letrozole demonstrates high affinity for CYP19A1 and exhibits potent inhibition of aromatase activity in experimental systems. Its well-characterized interaction with the aromatase active site has established it as a reference compound for studies of enzyme inhibition, concentration-response relationships, inhibitor selectivity, and comparative aromatase pharmacology. These characteristics make letrozole a valuable tool for mechanistic investigations of CYP19A1 function and regulation.
Research Use Disclaimer
All product information is provided for educational and laboratory research reference only. Any form of introduction into humans or animals is prohibited. Handle only in licensed research settings in accordance with applicable laws and institutional protocols.
| Weight | 3 lbs |
|---|
Reviews
There are no reviews yet.